SubsidieMeestersDisruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Projectdetails
Introduction
Osteoarthritis (OA) is the most common cause of chronic pain in older persons in Europe and is the leading cause of disability. The disease is a condition affecting the joint cartilage and subchondral bone and is frequently accompanied by pain, stiffness, and long-term disability.
Symptoms and Impact
Chronic pain is the most prominent symptom in most people with OA and is the most important determinant of disability in patients with osteoarthritis.
Current Treatment Guidelines
Treatment guidelines for OA pain management uniformly recommend a range of pharmacological therapies, including:
- Paracetamol
- NSAIDs
- Opioids
These are to be used together with non-pharmacological therapies. However, such therapies are restricted by considerable side effects and limited efficacy, as well as country-specific restrictions on prescriptions (e.g., on opioid use).
Challenges for Patients
Given the risks and side effects associated with current therapies, the long-term outlook for OA patients is bleak. Currently, there exists no non-pharmacological effective therapy for OA pain management. OA patients are left with two options:
- Manage the debilitating chronic pain using over-the-counter and/or prescription medication, with all of the risks and side effects associated with those therapies.
- Try to independently cope with the pain and all of the personal, economic, and societal challenges that chronic pain presents.
Project Overview
Within the ambitious Arth-alleve project, we propose to develop a non-pharma, side-effect-free long-term therapy for OA patients, providing new hope to the growing cohort of European citizens affected by this debilitating disease.
Innovative Approach
The Arth-Alleve project will explore the concept of attaching neurotoxin molecules to hydrogel particles to enable the mechanism of nerve blocking to occur, with the hydrogel acting as a long-term anchor preventing migration of the molecule from the target site.
Conclusion
This project will truly transform the treatment of chronic OA pain and the quality of life of the large cohort of European patients suffering from the condition.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.998.885 |
| Totale projectbegroting | € 1.998.885 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 29-2-2028 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITY OF GALWAYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
In Silico Trials for Cartilage Regenerative Medicine ApplicationsThe INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials. | ERC Consolid... | € 2.212.385 | 2023 | Details |
Oral oxytocin for abdominal painThis project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens. | ERC Proof of... | € 150.000 | 2023 | Details |
Modelling trajectories and mechanisms of childhood hip dysplasiaThe HIPSTAR project aims to identify and prevent hip dysplasia in children to reduce the risk of developing osteoarthritis in adulthood by studying growth patterns and causal factors. | ERC Advanced... | € 2.499.373 | 2023 | Details |
A mechanism-based approach to the prevention of chronic pain and its comorbid mental disordersThis project aims to transform chronic pain treatment by identifying transdiagnostic mechanisms and developing digital and virtual reality interventions to prevent chronicity and associated mental disorders. | ERC Advanced... | € 2.424.481 | 2024 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
In Silico Trials for Cartilage Regenerative Medicine Applications
The INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials.
Oral oxytocin for abdominal pain
This project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens.
Modelling trajectories and mechanisms of childhood hip dysplasia
The HIPSTAR project aims to identify and prevent hip dysplasia in children to reduce the risk of developing osteoarthritis in adulthood by studying growth patterns and causal factors.
A mechanism-based approach to the prevention of chronic pain and its comorbid mental disorders
This project aims to transform chronic pain treatment by identifying transdiagnostic mechanisms and developing digital and virtual reality interventions to prevent chronicity and associated mental disorders.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
INTELLECTUALSDit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis. | 1.1 - Het ve... | € 479.529 | 2024 | Details |
A breakthrough active immunotherapy for the treatment of osteoarthritisPeptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Bestrijding Artrose met Operatie RobotsDit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Rebuilding Joint Surface to Prevent Pain and ImmobilityAskel's COPLA® implant promotes cartilage regeneration and quick rehabilitation to prevent osteoarthritis, aiming to establish a gold standard for pain-free joint movement and improved quality of life. | EIC Accelerator | € 2.499.000 | 2022 | Details |
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
INTELLECTUALS
Dit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis.
A breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.
Bestrijding Artrose met Operatie Robots
Dit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren.
Rebuilding Joint Surface to Prevent Pain and Immobility
Askel's COPLA® implant promotes cartilage regeneration and quick rehabilitation to prevent osteoarthritis, aiming to establish a gold standard for pain-free joint movement and improved quality of life.